J. Donald Woodruff Professor of Gynecology, The Johns Hopkins Hospital, Department of Gynecology and Obstetrics, Baltimore, MD (USA) Education/Training: Swarthmore College B.A. 1954 English Literature Cornell University M.D. 1958 Medicine Bellevue Hospital (Cornell Medical Division) Internship 1958-1959 Medicine Kings County Hospital Residency 1959-1963 OB/GYN Worcester Foundation for Experimental Biology Fellowship 1961-1962 Reproductive Biology Professional Experience: 1962-63 Assistant Instructor, Department of Obstetrics and Gynecology State University of New York Downstate Medical Center 1965-66 Associate, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine 1966-70 Assistant Professor, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine 1970-71 Associate Professor, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine 1971-84 Professor, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine 1981-82 Visiting Professor, Department of Obstetrics and Gynecology, Kyoto University Medical School, Japan (sabbatical- leave) 1971-84 Professor Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine & Chairman Department of Obstetrics and Gynecology Pennsylvania Hospital 1987 Visiting Professor, Department of Obstetrics and Gynecology, Keio University, Tokyo, Japan 1991-98 Joint Appointment, Professor, Department of Population Dynamics, The Johns Hopkins University School of Hygiene and Public Health 1994-Present J. Donald Woodruff Professor of Gynecology, Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine 1999-Present Joint Appointment, Department of Biochemistry, The Johns Hopkins University School of Hygiene and Public Health. Honors and Awards: 1970-71 The Christian R. and Mary F. Lindback Foundation Distinguished Teaching Award, University of Pennsylvania School of Medicine 1970 Honorary Degree – Master of Arts – University of Pennsylvania 1974 Alpha Omega Alpha – Elected to Faculty Membership 1977 Clarence C. Briscoe Teaching Award- Pennsylvania Hospital 1984 Serono Lecturer, 40th Annual Meeting, American Fertility Society 1988 Third Memorial John Rock Lecturer, University of Pennsylvania School of Medicine 1988 Eighteenth Annual William Studdiford Visiting Professor, New York University School of Medicine 1988 Eleventh Annual Robert B. Greenblatt Lecturer, Medical College of Georgia 1991 Ninth Isadore Seigel Memorial Lecturer, University of Maryland School of Medicine 1995 Elected to Membership, Institute of Medicine, National Academy of Science 1996 First Honored Alumnus Lecturer, Alumni Day, Department of Obstetrics and Gynecology, SUNY Health Science Center at Brooklyn, September 27, 1996 1996 Alvin F. Goldfarb Lecturer, Vanderbilt University, October 26, 1996 1997 25th Annual S. Leon Israel Visiting Lecturer, Pennsylvania Hospital, June 26, 1997 1997 11th Annual Griff T. Ross Memorial Lecturer, NIH, September 26, 1997 1999 16th Annual Howard and Georgeanna Jones Lectureship, Johns Hopkins, December 9, 1999 2000 Poly Prep Country Day School; Distinguished Achievement Award; April 29, 2000 2000 P.A.R.E.S. Philadelphia Area Reproductive Endocrinology Society Recognition of Excellence Award; May 4, 2000 2002 Nokes Lecturer; University of Virginia Department of Obstetrics and Gynecology; May 10-11, 2002 Publications: Books MODERN TRENDS IN INFERTILITY AND CONCEPTION CONTROL. Vol. 1 Ed. by Wallach, E.E. and Kempers, R.D., Williams and Wilkins Co. Baltimore, Md. (1979) MODERN TRENDS IN INFERTILITY AND CONTRACEPTION CONTROL. Vol. II Ed. by Wallach, E.E. and Kempers, R.D., Harper and Row Publishers, Philadelphia, Pa. (1982) MODERN TRENDS IN INFERTILITY AND CONTRACEPTION CONTROL. Vol. III Ed by Wallach, E.E. and Kempers, R.D. Yearbook Medical Publishers, Chicago, IL (1985) MODERN TRENDS IN INFERTILITY AND CONTRACEPTION CONTROL. Vol. IV Ed by Wallach, E.E. and Kempers, R.D., Yearbook Medical Publishers, Chicago, IL (1988) REPRODUCTIVE MEDICINE AND SURGERY. Edited by Wallach, E.E. and Zacur H.A. Mosby Yearbook Medical Publishers, St. Louis, MO (1994) THE JOHNS HOPKINS MANUAL OF GYNECOLOGY & OBSTETRICS, first edition, edited by Lambrou NC, Morse AN, Fox HE, Wallach EE, Lippincott Williams and Wilkins, Philadelphia, PA (1999) THE JOHN HOPKINS MANUAL OF GYNECOLOGY & OBSTETRICS, second edition, edited by Bankowski BJ, Hearne AE, Lambrou NC, Fox HE, Wallach EE. Lippincott Williams and Wilkins, Philadelphia PA (2002) HYSTERECTOMY: EXPLORING YOU OPTIONS. Wallach EE, Eisenberg E. Johns Hopkins University Press, Baltimore, MD (2003) Bibliography Vlahos NP, Dragisic KG, Wallach EE, Burrough FH, Fluck S, Rosenthal DL. Clinical significance of atypical squamous cells of undermined significance: an analysis based on histologic diagnosis. The Amer. J of Obstet and Gynecol 2000;185:855-900. Phelps JY, Wallach EE, and Moghissi KS. Evaluation and Management of Infertility in (Ransom SB {Ed}) Practical Strategies in Infertility. Philadelphia, WB Saunders and Company, 2000, PP 609-627. Edwards BE, Gearhart JD, Wallach EE. The human pluripotent stem cell: Impact on Medicine and Society. Fertil Steril 2000; 74(1): 1-7 Jurema MW, Wallach EE, Blumenthal PD. Miferistone for Medical Abortion: A Review. Postgraduate Obstetrics and Gynecology, June 2001, Volume 21, Number 13. Jurema MW, Valhos N, Wallach EE. Reproductive Health and Cystic Fibrosis. Postgraduate Obstetrics and Gynecology, January 2001, Volume 21, Number 2. Whelan III, J, Vlahos NP, Jurema MW, Wallach EE. Contemporary Management of Leiomyomata. W.B. Saunders, (eds. Ransom S, Dombrowski M, Evans M, Ginsburg K). Contemporary Therapy in Obstetrics and Gynecology. 2002;367-370. Posada MN, Valhos NP, Jurema MW, Bracero NJ, Wallach EE, Garcia JE. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization. Fertil Steril. 2003 July; 80(1):103-10. Vlahos NP, Wallach EE. Uterine Myomas An Overview of Development, Clinical Features and Management. Obstetrics and Gynecology. 2004 August; 104 (2): 393-406. Zhao Y, Valhos N, Wyncott D, Petrella C, Garcia J, Zacur H, Wallach EE. Impact of semen characteristics on the success of intrauterine insemination. Journal of Assisted Reproduction and Genetics. 2004; Vol 21 (no. 5); 143-148. Lyerly A, Belsford E, Bankowski B, Faden R, Wallach E. A quantitative study of individuals’ attitudes regarding their cryopreserved embryos. JFFS Congress Proceedings (in press 2004). Bacero JH, Vlahos NP, Jurema MW, Wallach EE, Garcia JE. Triggering ovulation with two doses of a GnRH agonist after treatment with a GnRH antagonist in IVF-ET. Human Reproduction (Submitted). Lai T-H, Shih I-M, Vlahos N, Ho Z, Wallach EE, Zhao J. Differential expression of L-selectin ligands in the endometrium during the menstrual cycle (in preparation). Abstracts: Posada M, Jurema M, Valhos N, Bracero N, Wallach EE, Garcia J. Should women with poor prognostic factors for controlled ovarian hyper-stimulation undergo in vitro fertilization (COH-IVF) using Ganirelix? American Society for Reproductive Medicine 2001 Annual Meeting. Wyncott D, Vlahos N, Garcia J, Zacur H, Wallach EE, Zhao Y. Intrauterine insemination: Which sperm characteristic matters? ASRM, October 2003. Bankowski B, Zhao Y, Zacur H, Wallach E, Garcia J, Vlahos N. High pregnancy rates with GnRH antagonists and oocyte donors. (ESHRE), Madrid, Spain, June 2003. Coker L, Lawler C, Zhao Y, Bankowski B, Wallach E, Vlahos N. Follicular diameter and hCG administration do not affect pregnancy rates after clomiphene citrate and intrauterine insemination. ASRM Poster Presentation San Antonio Texas, October 2003. Jurema M, Vieira A, Bankowski B, Zhao Y, Wallach E, Zacur H. Ejaculatory abstinence less than 3 days results in a higher pregnancy rate (PR) following intrauterine insemination (IUI). ASRM Oral Presentation, San Antonio, Texas. October 2003. Wyncott D, Vlahos N, Garcia J, Zacur HA, Wallach EE, Zhao Y. Intrauterine insemination; which sperm characteristics matter? ASRM Oral Presentation. San Antonio Texas. October 2003. Bankowski B, Bracero N, King J, Garcia J, Wallach EE, Vlahos N. Ovulation triggering of oocyte maturation with leuprolide acetate versus Human Chorionic Gonadotropin (hCG). Scientific Program, Berlin, Germany, June 27-30, 2004.Read More

MARIO PRETI born in Arona (Italy) June 5th 1960. Specialization in Gynecology and Obstetrics in 1990 at the University of Turin, Italy. Specialization in Medical Oncology in 1994 at the University of Turin. From 1992 Assistant then, up to now, Deputy Director at the Obstetrics and Gynecology Department, University of Turin-St. Anna Hospital (the second greatest Gynecological Hospital in Europe). Head of Urodynamic Unit of the Department of Gynecology. Regional Referent for diagnosis and treatment of lower genital tract neoplasia In the Colposcopy Unit at the same Department. Doctor Mario Preti belongs to the Faculty of the Specialization School in Gynecology and Obstetrics, University of Turin since 1992 and of the School of Midwifery since 1986. At present he is holding a course on “Prevention, diagnosis and treatment of Female Genital Tract Neoplasms” and a course on “Surgical operation in Obstetrics”. Fellow of the ISSVD (International Society for the Study of Vulvo-vaginal disease) from 1990. He is Chair of the Oncological Committee on Superficially invasive carcinoma. Founding Member of the Italian Interdisciplinary Society of Vulvology (SIIV), Assistant Secretary from the foundation in 1996 up to 2004, and then Treasurer. Fellow of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV) since 1985. He is member of the Scientific Committee since 1998 and he is National Referent for Vulvar Pathology. Member of Scientific Committee of IFCP (International Federation of Colposcopy and Cervical Pathology) since 2005. Doctor Mario Preti has participated as invited speaker to 25 International Congresses on vulvar and cervico-vaginal diseases. He published more than 200 scientific papers. Some of them have been published on International Journals: British Journal of Dermatology, British Journal of Obstetrics and Gynecology, Cancer, Clinical Obstetrics and Gynecology, The Journal Lower Genital Tract Disease, Journal of Surgical Oncology, The Journal of Reproductive Medicine, Obstetrics and Gynecology (in press). As attested by his scientific publications doctor Mario Preti collaborates with: European Institute of Oncology (Milan Italy), National Cancer Institute (Milan, Italy), Regional Cancer Center (Aviano, Italy), National Cancer Institute Regina Elena (Rome, Italy), Department of Gynecology University of Bologna (Bologna Italy), Department of Pathology University of Gainesville (Florida, USA), Department of Gynecology, Academic Medical Center/NKI-AvL, Amsterdam (The Netherlands), Department of Obstetrics and Gynecology Erasmus University M.C., Rotterdam, (The Netherlands), Department of Obstetrics and Gynecology, Centre Hospitalier de Creteil, (France).Read More

Professor of Obstetrics and Gynecology Vice Chairman Department of Obstetrics and Gynecology Vanderbilt University Medical Center North B1100, Nashville, TN (USA) 37232-2519 Office telephone: (615) 343-5227 Fax: (615) 343-8881 e-mail: frank.boehm@vanderbilt.edu Dr. Frank H. Boehm is Professor of Obstetrics and Gynecology and Vice Chairman of the Department of Obstetrics and Gynecology at Vanderbilt Medical Center in Nashville, TN. He is the former Director of Maternal Fetal Medicine at Vanderbilt Medical Center as well as the former Chair of the Vanderbilt Medical Center’s Ethics Committee. Dr. Boehm is a graduate of Vanderbilt Medical School and the Yale Internship and Residency Program. He is Board certified in Obstetrics and Gynecology and Maternal Fetal Medicine and has authored over 200 scientific publications as well as co-editing a major medical textbook. Dr. Boehm has also authored Doctor’s Cry, Too: Essays from the Heart of a Physician and Building Patient Doctor Trust which addresses the issue of physician-patient communication and the need for doctors to build trusting relationships with their patients. Dr. Boehm has served on national committees and is a reviewer of major scientific publications in his field. In addition, he has spoken throughout the United States, Canada, Mexico, Europe and the Middle East. He currently authors an op-ed column in the Tennessean, a Nashville newspaper, on medical issues. He has received numerous honors, including, Vanderbilt Medical Center Faculty Award for teaching medical students, residents, and/or fellows in the clinical setting and was the first recipient of the Frank H. Boehm Award for contributions to continuing medical education. Dr. Boehm has three children and five grandchildren. He and his wife, Julie, reside in Nashville and Boca Raton, Florida. Dr. Boehm can be reached at his email, frank.boehm@vanderbilt.edu, office telephone, (615) 343-5227, fax, (615) 343-8881.Read More

Professor of Obstetrics and Gynecology Chief, Division of Maternal-Fetal Medicine University of Utah Health Sciences Center (UUHSC) 30 North 1900 East SOM 2B200 Salt Lake City, UT 84132 (USA) Tel: 801-585-5156 Fax: 801-585-2594 E-mail: robert.silver@hsc.utah.edu Education and Training: INSTITUTION AND LOCATION DEGREE YEAR (s) FIELD OF STUDY University of Pennsylvania, Philadelphia, PA BA 1982 Microbiology Medical College of Pennsylvania, Philadelphia, PA MD 1986 Medicine University of Colorado Health Sciences Center, Denver, CO Residency 1986-1990 Obstetrics and Gynecology University of Utah Health Sciences Center (UUHSC), Salt Lake City, UT Fellowship 1990-1994 Maternal-Fetal Medicine A. Positions and Honors Positions 1990-1991 Clinical Instructor, Department of Ob/Gyn, UUHSC, SLC, UT 1992-1994 Instructor, Department of Ob/Gyn, UUHSC, SLC, UT 1994-1998 Assistant Professor, Department of Ob/Gyn, UUHSC, SLC, UT 1998-2006 Associate Professor with tenure, Department of Ob/Gyn, UUHSC, SLC, UT 2006-present Professor with tenure, Department of Ob/Gyn, UUHSC, SLC , UT 1995-2003 Residency Director, Department of Ob/Gyn, UUHSC, SLC, UT 2001-present Medical Director of Labor and Delivery, UUHSC, SLC, UT 2000-present Division Chief, Maternal Fetal Medicine, Department of Ob/Gyn, UUHSC, SLC, UT Honors 1985 Kurt Pauker Achievement Award for Excellence in Microbiology 1986 Alpha Omega Alpha 1993-1998 Research Scientist Development Program, National Institutes of Health 2000 Poster Award (best of session): IgA beta-2-glycoprotein-I Antibodies are Elevated in Women with Unexplained Recurrent Spontaneous Abortion and Unexplained Fetal Death, Society for Gynecologic Investigation 2001 Poster Award (best of session): Heparin-induced Thrombocytopenia is Rare in Pregnancy, Society of Perinatal Obstetricians 18th Annual Meeting 2003 Poster Award (best of meeting): Stillbirth in Utah from 1995-2001 B. Peer-Reviewed Publications Select peer-reviewed publications (in chronological order) Mitchell MD, Edwin SS, Lundin-Schiller S, Silver RM, Smotkin D, Trautman MS. (1993). Mechanism of interleukin-1 beta stimulation of human amnion prostaglandin biosynthesis: mediation via a novel inducible cyclooxygenase. Placenta 1993; 14:615-25. Edwin SS, Branch DW, Scott JR, Silver RM, Mitchell MD. Cyclosporin A attenuates increased prostaglandin and thromboxane production in response to various stimuli in human decidua. Am J Reprod Immunol 1993;30: 154-9. Silver RM, Draper ML, Scott JR, Lyon JL, Byrne SL, Ashwood EA, Branch DW. Unexplained elevations of maternal serum alpha-fetoprotein in women with antiphospholipid antibodies: A harbinger of fetal death. Obstet Gynecol 1993; 83:150-5. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch DW. Clinical consequences of antiphospholipid antibodies: An historical cohort study. Obstet Gynecol, 1994;83:372-7. Mitchell MD, LaMarche S, Adamson S, Coulam C, Silver RM, Edwin SS. Regulation of intrauterine prostaglandin biosynthesis interactions between protein kinase C and interleukin 1Β. Prost Leuk EFA 1994;50:137-40. Silver RM, Edwin SS, Trautmna MS, Simmons DL, Branch DW, Dudley DJ, Mitchell MD. Bacterial lipopolysaccharide mediated fetal death: Production of a newly-recognized form of inducible cyclooxygenase (COX-2) in murine deciduas in response to lipopolysaccharide. J Clin Invest 1995;93:725-31. Silver RM, Pierangelli SS, Gharavai AE, Harris EN, Edwin SS, Salafia CM, Branch DW. Induction of high levels of anticardiolipin antibodies in mice by immunization with Β2-glycoprotein 1 does not cause fetal death. Am J Obstet Gynecol 1995;173L1410-5. Silver RM, Porter TF, van Leeuwen I, Coulam C, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: Clinical consequences of low titers. Obstet Gynecol 1996;87:494-500. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489-93. Edwin SS, Branch DW, Scott JR, Silver RM, Dudley DJ, Mitchell MD. Cyclosporin A inhibits prostaglandin E2 production by fetal amnion cells in response to various stimuli. Prostaglandins 1996;52:51-61. Branch DW, Silver RM. Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss? Lupus 1996;5:409-13. Branch DW, Silver RM, Pierangeli SS, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant are not associated with recurrent pregnancy loss. Obstet Gyencol 1997;89:549-55. Silver RM, Edwin SS, Umar F, Dudley DJ, Branch DW, Mitchell MD. Bacterial lipopolysaccharide-mediate fetal death: The role of interleukin-1. Am J Obstet Gynecol 1997;176:544-9. Silver RM, Pierangeli SS, Edwin SS, Umar F, Harris EN, Scott JR, Branch DW. Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who test negative for lupus anticoagulant and anticardiolipin antibodies. Am J Obstet Gynecol 1997;176:628-33. Silver RM, Smith LA, Edwin SS, Oshiro BT, Scott JR, Branch DW. Variable effects of immunoglobulin G fractions from women with antiphospholipid antibodies on murine pregnancy. Am J Obstet Gynecol 1997;177:229-33. Coulam CB, Clark DA, Beer AE, Kutteh WH, Silver RM, Kwad J, Stephenson M. Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1997;38:57-74. Edwin SS, Mitchell MD, Silver RM, Branch DW, Dudley DJ. Ceramide stimulates prostaglandin production by human amnion and decidual cells J Soc Gynecol Invst 1997;4:274-8. Gharavi AE, Cucurull E, Tang H, Silver RM, Branch DW. Effect of antiphospholipid antibodies on beta-2-glycoprotein I-phospholipid interaction. Am J Reprod Immunol 1998;39:310-5. Kutteh WH, Rote NS, Silver RM. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol 1999;41:133-154. Pregnancy loss study group (Branch DW, Druzin M, El-Sayed Y, Esplin MS, Hrager J, Peaceman AM, Silver RK, Silver RM, Spinnato J). A multicenter, controlled, pilot study of intravenous immune globulin treatment antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 2000;182:122-7. Van-Horn JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of gestational tissues from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004;25:642-8. Ornoy A, Chen L, Silver RM, Mosmann TR, Miller RK. Maternal autoimmune diseases and immunologically-induced embryonic and feto-placental damage. Birth Defects Res Part A Clin Mol Teratol 2004;70:71-81. Frias AE, Luikenaar RA, Sullivan AE, Porter TF, Branch DW, Silver RM. Poor obstetric outcome in subsequent pregnancies in women with prior fetal death. Obstet Gynecol 2004;104:521-6. Sullivan AE, Silver RM, LaCoursiere DY, Porter TF, Branch DW. Does recurrent aneuploidy contribute to recurrent miscarriage? Obstet Gynecol 2004;10:784-8. Sullivan AE, Nelson L, Rice JA, Porter TF, Branch DW, Silver RM. The factor V Leiden and the G20210A prothrombin gene mutations are rare in women with fetal death. Am J Reprod Immunol 2005;54;1-4. Sullivan AE, Nelson L, Silver RM, Frias AE, Porter TF, Branch DW. The aryl hydrocarbon receptor nuclear tranlsocator gene polymorphism in patients with recurrent miscarriage. Am J Reprod Immunol 2006;55(1): 51-3 Silver RM, Landon MB, Rouse DC, Leveno JK, Spong CY, Thom EA, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006;107(6): 1226-32. Silver RM. Fetal Death. Obstet Gynecol 2007;109(1):153-67. Silver RM, Varner MW, Reddy U, Goldenberg R, Pinar H, Conway D, Bukowski R, Carpenter M, Hogue C, Willinger M, Dudley D, Saade G, Stoll B. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007;196:433-44. Warren JE, Silver RM, Nelson L, Dalton J, Porter TF, Branch DW. Cervical insufficiency: a genetic condition? Collagen 1?1 intron SP1 and transforming growth factor-? ARG-25-PRO polymorphisms in women with cervical insufficiency. Obstet Gynecol 2007;110:619-24. Raju TN, Nelson KB, Ferriero D, Lynch JK; NICHD-NINDS Perinatal Stroke Workshop Participants. Pediatrics 2007;120:609-16. Holmgren C, Esplin MS, Hamblin S, Esplin MS, Molenda M, Silver RM. Evaluation of the use of anti-TNF-alpha in an LPS-induced murine model. J Reprod Immunol 2008; Epub, April 21. Silver RM. New anticoagulants and pregnancy. Obstet Gynecol 2008;112:419-20. Silver RM. Immune activation early in pregnancy: trouble down the road. Am J Obstet Gynecol 2008, 199;327-8. Holmgren C, Porter TF, Varner MW, Aagard K, Silver RM. Hyperemesis in pregnancy: A comparison of treatment strategies. Am J Obstet Gynecol, 2008;198:56e1-4. Turok DK, Gurtcheff S, Esplin MS, Shah M, Simonsen SE, Shah M, Trauscht-Van Horn J, Silver RM. Second trimester termination of pregnancy: A review by site and procedure type. Contraception 2008;77:155-61 Peltier MR, Faux DS, Hamblin SD, Cooper C, Silver RM, Esplin MS. Effect of aspirin treatment on TNF-? Production by women with a history of preterm birth. J Reprod Immunol 2009;80:109-14. Warren JE, Silver RM, Branch DW, Porter TF. Thromboprophylaxis and pregnancy outcomes in asymptomatic women with thrombophilias. Am J Obstet Gynecol 2009;200:281.e1-5. Warren JE, Nelson L, Esplin MS, Silver RM. Interleukin-10 polymorphisms and cervical insufficiency. Am J Obstet Gynecol 2009;201:372-4. Manuck TA, Eller AG, Esplin MS, Stoddard G, Varner MW, Silver RM. Outcomes of expectantly managed preterm premature rupture of membranes occurring ? 24 weeks gestation. Obstet Gynecol 2009;114:29-37. Reddy UM, Goldenberg R, Silver R, Smith GCS, Pauli RM, Wapner RJ, et al. Stillbirth classification: developing an international consensus for research: Executive summary of NICHD workshop. Obstet Gynecol 2009;114:901-14. Manuck TA, McLean, Varner MW, Silver RM. Preterm premature rupture of membranes: does the duration of latency influence neonatal outcome? Am J Obstet Gynecol 2009;201:414-6. Warren JE, Turok DK, Maxwell TM, Brothman AR, Silver RM. Array comparative genomic hybridization (aCGH) for genetic evaluation of fetal loss between 10 and 20 weeks gestation. Obstet Gynecol 2009;114:1093-1102. Clark EAS, Lacoursiere DY, Byrne JLB, Ponder R, Silver RM, Esplin MS. Reliability of fetal MCA velocity: a randomized controlled trial of sonographer training. J Ultrasound Med 2009;28:19-25. Grosvenor Eller A, Silver RM, Zempolich K, Soisson P, Simonson SE. Optimal management of placenta accreta. Br J Obstet Gynecol 2009;116:648-54. Peltier MR, Faux DS, Hamblin SD, Silver RM, Esplin MS. Cytokine production by peripheral blood mononuclear cells of women with a history of preterm birth. In press, J Reprod Immunol. Silver RM, Zhao Y, Spong C, Caritis SN, Sibai B, Wendel G Jr., et al. Prothrombin gene G20210A mutation and obstetric complications: a prospective cohort. In press, Obstet Gynecol. C. Research Support Ongoing Support NIH/NICHD 1U10HD063053-01 Preterm Birth in Nulliparous Women: An Understudied Population (Silver)12/01/2009-11/30/2014 This Network will design and execute a prospective, longitudinal cohort study of 10,000 nulliparous women. The research protocols developed will determine characteristics that influence and/or predict adverse pregnancy outcomes in nulliparous women including genetics, epigenetics, physiological response to pregnancy, interaction with environmental exposures, fetal growth and development, and placental development and function. Role: PI NIH/NICHD 3U10HD045944-05S2 Research on the Scope and Causes of Stillbirth in the United States (Silver)09/26/2003–07/31/2009NCX The major goals of this project are to develop a network of collaborating academic centers to study the extent and causes of stillbirth and to develop methods for stillbirth prevention. Role: PI NIH/NICHD HHSN267200603423C / N01DK63423 (Silver)09/30/2006-09/29/2011 The Effects of Aspirin in Gestation and Reproduction The purpose of this contract is to evaluate the effect of daily low-dose aspirin on all phases of reproduction beginning at preconception and continuing throughout pregnancy, including implantation and live births. Role: PIRead More

President Women’s Health and Education Center (WHEC) NGO in Special Consultative Status with the Economic and Social Council of the United Nations e-mail: Rita@WomensHealthSection.com Dr. Rita Luthra is President of The Women’s Health and Education Center (WHEC) which is NGO (non-governmental organization) in Special Consultative Status with the Economic and Social Council of the United Nations. It is also affiliated with the World Health Organization (WHO), PMNCH (Partnership for Maternal and Child Health at WHO), The Economic and Social Council (ECOSOC), UN Department of Public Information ( UN DPI), UN Women, UN University (UNU), UN Foundation (UNF), and Every Woman Every Child Global Strategy initiative of the UN Secretary-General. Established in 2001, The Women’s Health and Education Center (WHEC) undertakes initiatives with the United Nations (UN) and the World Health Organization (WHO), to achieve the hopes and dreams of Sustainable Development Goals (SDGs), with special focus on Maternal and Child Health. Dr. Luthra has worked with various international organizations, such as the UNA-USA, Peace Corps, Population Council and World Health Organization. Dr. Luthra’s main interest is international health and development. She has 25 years of expertise in the project/program development at the National and International levels with various respectable international organizations, and innovative health technology systems such as telemedicine, online distance education and various e-Health management systems. The use of information science and telecommunications to support the practice of medicine when distance separates the caregiver from the patient is the way forward to make medical care more affordable and more accessible in every country. A strong and vital health workforce is an investment in health for today and the future. It has profound effect on all the citizens of the world, political, social, and economic systems. There are 3 leading purposes of the health-related uses of information and communication technologies (ICT) in low- and middle-income countries: To extend geographic access to health care; To improve data management; and To facilitate communication between patients and physicians outside the physician’s office. In 2018 at High Level Political Forum (HLPF), Dr. Luthra presented WHEC Global Health Line’s (WGHL’s) LINK (Learning and Innovation Network for Knowledge Solutions) Access Project – To provide access to reproductive health research worldwide, at UN Headquarters, NYC, New York (USA). Available @ UN Web TV: http://webtv.un.org/watch/player/5807660229001 Dr. Luthra was born and grew up in Rajasthan, India and currently resides in Massachusetts, USA. She received her education and medical degree (Bachelor of Medicine and Bachelor of Surgery) M.B.B.S. from University of Rajasthan, Jaipur (India) in 1974. M.D. (Doctor of Medicine) in Obstetrics and Gynecology, in 1978 from The Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh (India). After finishing the residency in Obstetrics and Gynecology at St. Elizabeth’s Medical Center, Boston, MA (USA) she received Fellowship in Obstetrics and Gynecology from the American College of Obstetrics and Gynecology, in 1986. She practiced Obstetrics and Gynecology mostly in Massachusetts (USA) till November 2015. Currently working with the UN and WHO on various initiatives to achieve Universal Health Care (UHC) and improve maternal and child health. Dr. Luthra is Editor-in-Chief of the e-learning publications: http://www.WomensHealthSection.com and WHEC Update. The initiatives of WHEC are also posted on CSO Net (Civil Society Net) under Best Practices and Projects on World Map ID # 364, title: Continuing Medical Education for the Globalized World. http://www.WomensHealthSection.com – knowledge that touches patients, is a vision for the globalized world. Please visit our Letters of Support Page: http://www.womenshealthsection.com/whec/letters We welcome everyone. Dedicated to Women’s and Children’s Healthcare and Wellbeing WorldwideRead More

THE WOMEN’S HEALTH AND EDUCATION ORGANIZATION, INC. [Read the WHEO, Inc. Mission Statement] AND WOMEN’S HEALTH AND EDUCATION CENTER (WHEC) NGO in Special Consultative Status with ECOSOC of the United Nations AND WomensHealthSection.Com BY-LAWS Article I Name and Location 1.1 Name: The name of this non-profit organization is, THE WOMEN’S HEALTH AND EDUCATION ORGANIZATION, INC. Its acronym is: WHEO, Inc. It is at WOMEN’S HEALTH AND EDUCATION CENTER (WHEC), NGO in Special Consultative Status with the ECOSOC of the United Nations. Their web-site domain name is: WomensHealthSection.Com. 1.2 Location: The principal office is in Longmeadow, Massachusetts (USA). The Board of Directors may change the location of the principal office, upon filing a certificate with the Secretary of State of The Commonwealth of Massachusetts (USA). Article II Purpose 2.1 Purpose: The Corporation is operating as a non- profit organization for the purpose of supporting and improving the educational opportunities and general health of women and particularly women of the developing countries. Article III Membership 3.1 Members: Any persons or institutions interested in the purpose of the corporation shall be eligible for membership. The Board of Directors may from time to time establish such classes of membership as may be appropriate. In any event, all members, regardless of classification, shall have equal voting rights. 3.2 Membership Contributions: The Directors may from time to time establish membership contributions for the various classes of membership. Notices of annual membership contributions shall be sent, to all members. Any member who fails to pay the applicable membership contribution, within three months, following the sending of notice shall be dropped from membership, and shall lose all privileges of a member of the corporation. Article IV Meetings 4.1 Annual Meeting: The annual meeting of the corporation shall be held on the third Thursday on September of each year or at such other time in the month of September as the Directors shall determine. The annual meeting may be held at the principal office of the corporation, or at such other place as the Directors may determine. 4.2 Special Meetings: Special meetings of the corporation may be called by the President, a majority of the Directors, or upon written request of the majority of the members of the corporation delivered to the President. 4.3 Notice: All meetings of the corporation shall be called by giving not less than one week’s notice to each member of the corporation by mail so far as their addressed may be known or by publication of a notice in a newspaper published in Springfield, Massachusetts. 4.4 Quorum: A simple majority of members eligible to vote shall constitute a quorum for the transaction of all business. Article V Board of Directors 5.1 Number and Election: The Board of Directors shall consist of the President, the Secretary, the Treasurer and not less than three and not more than ten other members of the corporation elected annually by the members at the annual meeting. 5.2 Tenure: The Directors elected at any annual meeting shall be elected for three years or such shorter length of term as will cause the term of office of approximately one third of the elected members of the Board to expire each year. No Director shall serve for more than six consecutive years, except that an officer may, if re-elected, continue to serve in that office for not more than three additional consecutive years. Directors who have served the maximum term may be re-elected to the Board after an interval of not less than one year. 5.3 Meetings: Meetings of the Board of Directors shall be called by the President, or upon the written request of three Directors. 5.4 Notice: Notice of all meetings of the Board of Directors shall be mailed to each Director at least seven days prior to the date of any meeting. 5.5 Quorum: A simple majority, or, if there are more than ten Directors, one-third of the then in office, shall constitute a quorum. 5.6 Powers: The Board of Directors shall have the general direction, control and management of the property and the affairs of the Society except such as are to be exercised exclusively by the members of the corporation by law or by these By-Laws. 5.7 Audit: The Board of Directors shall arrange for an annual audit of the accounts of the Treasurer and the financial affairs of the corporation. 5.8 Honorary Directors: Any Director who has served as a Director for not less three years may be elected an Honorary Director at an annual meeting. An Honorary Director shall hold office for the remainder of his or her life, unless re-elected an active Director or removed for good and sufficient cause by vote of the members of the corporation. Honorary Directors shall not be voting members of the Board of Directors. (The Honorary Chairperson shall not be considered an Honorary Director). Article VI Officers 6.1 Number and Election: The officers of the corporation shall be a President, a Secretary and a Treasurer. The officers shall be elected annually by the members at the annual meeting and shall hold office for two years, and until their successors are elected. Officers may be re-elected. The Directors may fill vacancies in any office until the next annual meeting. 6.2 Honorary Chairperson and Chairperson: The Honorary Chairperson and the Chairperson shall have the usual duties of their respective offices and such other duties as may be assigned to them from time to time by the Directors. There is no limit other than the limit placed on the term of any other Directors to their term. 6.3 President: The President shall have the usual duties of such office and such other duties as may be assigned to them from time to time by the Directors. The President shall be a member of all Committees ex officio. No President shall be elected by the members to the same office for more than six consecutive terms. The President shall be executive officer of the corporation and, subject to the instructions of the Board of Directors, shall be responsible for the general operation of the corporation. So far as possible, the President shall attend all regular meetings of the corporation, the Board of Directors, and Standing Committees. The President shall prepare agendas for the annual meeting and special meetings of the corporation and for meetings of the Board of Directors. The President shall supervise the services of any employees. 6.4 Secretary: The Secretary shall record and maintain records of all proceedings of the corporation and of the Directors. These records shall be kept at the principal office of the corporation, and shall be open at all reasonable times to the inspection of any member. The Secretary shall be responsible for notices of annual meetings and special meetings of the corporation and meetings of the Board of Directors. 6.5 Treasurer: The Treasurer shall be the chief financial officer and the chief accounting officer of the corporation. The Treasurer shall be in charge of the corporation’s financial affairs, accounts, funds, securities and valuable papers, and shall keep full and accurate records thereof. The Treasurer shall supervise the keeping of correct records of receipts and expenditures in books maintained by the corporation. The treasurer shall present a report of the financial activities of the Society at each annual meeting. If required by the Directors, the Treasurer shall give bond for the faithful performance of the duties of the office in such sums and with such surety of sureties as the Directors may direct. 6.6 Vacancy: In the event of a vacancy in any office, the Directors elect one of their numbers to fill that office until the next annual meeting. Article VII Committees 7.1 Standing Committees: The Standing Committees of the corporation shall be Executive Committee, Nominating Committee, Finance Committee, Medical Advisory Committee and Educational Advisory Committee. 7.2 Executive Committee: The Executive Committee shall consist of the Chairman, the President, the Secretary, the Treasurer, and such other Directors as the President, with consent of the other Directors, may appoint for a term of one year. Directors may be reappointed. Two thirds of the members of the Executive Committee shall constitute a quorum for the transaction of business. Except as otherwise provided by law or by these By-Laws, the Executive Committee shall have and exercise all the powers of the Board of Directors during the intervals between meetings of the Directors. All actions of the Executive Committee shall be considered for ratification or confirmation at the next successive meeting of the Board of Directors. 7.3 Nominating Committee: The Nominating Committee shall consist of three members of the corporation, who need not be Directors. One member shall be elected each year at the annual meeting of the corporation for a term of three years. Any vacancy before the end of a term shall be filled by appointment by the President until the next annual meeting, at which time a member shall be elected to fill the balance of that term. No member of the Nominating Committee shall serve for more than six consecutive years. The Nomination Committee shall nominate one of more candidates for each office to be filled at the annual meeting of the corporation, including the Nominating Committee. At least one month before the Annual Meeting, the Nominating Committee shall file all nominations with the President, who shall immediately communicate those names to the Board of Directors. Nominations for any office to be filled at the Annual Meeting of the corporation may also be made by papers signed by three or more members of the corporation filed with the President at least two weeks before the Annual Meeting. Immediately upon receiving such nominations, the President shall immediately communicate those names to the Board of Directors. 7.4 Finance Committee: The members of the Finance Committee shall be appointed by the President to serve terms of three years, or such shorter length of term as will cause the term of office of approximately one-third of the members to expire each year. Members need not be Directors, and may be reappointed. The Finance Committee shall advise the Treasurer concerning the investment and management of the corporation’s funds and securities, and provide such additional advice and assistance as the Treasurer may request. 7.5 Medical Advisory: The members of Medical Advisory Committee shall be appointed by the President to serve terms of three years, or such shorter length of term as will cause the term of office of approximately one-third of the members to expire each year. Members need not be Directors, and may be reappointed. The Medical Advisory Committee shall advise the Board of Directors on those medical matters and of medical opportunities which it thinks the corporation should engage in furtherance of its stated purpose. 7.6 Educational Advisory Committee: The members of the Educational Advisory Committee shall be appointed by the President to serve terms of three years, of such shorter length of term as will cause the term of office of approximately one-third of the members to expire each year. Members need not be Directors, and may be reappointed. The Educational Advisory Committee shall advise the Board of Directors on those educational matters and of educational opportunities which it thinks the corporation should engage in furtherance of its stated purpose. 7.7 Other Committees: The President may appoint such other committees as the President and the Directors shall determine from time to time to be advisable and necessary. The chairperson of each such committee shall be a Director, but the other members of the committee need not be Directors. Members may be reappointed to such committees. Except as otherwise specifically set forth in these By-Laws, committees shall have such duties as may be assigned to them from time to time by the Directors. Article VIII Finance 8.1 Fiscal Year: The Fiscal year of the corporation shall begin on the first day of January in each year. 8.2 Accounts: The monies of the corporation shall be deposited in the name of the corporation in such banks or other financial institutions as the Directors shall designate. Funds shall be drawn only by checks or orders signed by such persons as the Directors shall designate. 8.3 Restrictions: The corporation is organized exclusively for charitable and educational purposes as specified in Section 501(c)(3) of Internal Revenue Code, as from time to time amended, herein after referred to as the code, and it shall not be operated for profit, and the corporation will nor carry on any activities not permitted to be carried on by a corporation exempt from federal income tax under the code. No part of its net earnings shall inure to the benefit of any member, director or any officer of the corporation or any private person, except that reasonable compensation may paid for services rendered to or for the corporation. No officer, director or member of the corporation or any private individual shall be entitled to share in the distribution of any of the corporate assets on dissolution of the corporation. No part of the corporation’s activities shall be the carrying on of propaganda or otherwise attempting to influence legislation or in intervening in any political campaign on behalf of any candidate for public office. Upon dissolution, all of the remaining assets and property of the corporation, after payment of necessary expensed thereof, shall be distributed to another corporation exempt under said section of the code, to be applied by such other corporation for those purposes of that corporation that are most similar to the purposes of this corporation, and no member or officer of this corporation shall profit thereby. Article IX Amendments 9.1 By the Directors: These By Laws, or any subsequent By-Law adopted by the Directors the members, may be amended or repealed by vote of two-thirds of the Directors then in office, except with respect to any provision of any By-Law which by law, the corporation’s Articles of Incorporation, or these By Laws, require action by the members of the corporation. Written notice stating the substance of any such amendment or repeal shall be given to the members not later than the annual meeting next following the vote of the Directors to amend or repeal. 9.2 By the Members: These By Laws, or any subsequent By Law adopted by the Directors or members, may be amended or repealed by vote of two-thirds of the members present at any meeting of the corporation. Written notice that the subject of amending or repealing By Laws is to come before the corporation shall be included in the notice of such meeting. 9.3 Restrictions: No amendment may be made which affects the non-profit status of the corporation or affects the disposition of assets on dissolution of assets on dissolution to another non-profit and income-tax-exempt organization.Read More

Dr. Maria M. Morales Suárez-Varela Professor Titular de Universidad Area de Medicina Preventiva y Salud Pública Universitat de Valencia Avd. Vicente Andrés Estellés s/n 46100 – Burjasot (Valencia) SPAIN Telephone/Fax: 34-963544951 e-mail: maria.m.morales@uv.es María Morales is a university professor at the University of Valencia (Spain) and doctor in Preventive Medicine and Public Health. She studied at the University of Córdoba (S. Spain) and holds a MD (1984) and PhD (1987). I entered the University of Valencia in 1988 as a full professor until the present day. Her training took her to the McGill University (Montreal, Canada), Summer WHO Epidemiology course in Florence, Italy under Professor Jorn Olsen, with whom I continue working. I have completed a statistics course at IARC (Lyon, France), and a course at Rotterdam University, Holland on Epidemiology and Public Health. I obtained my master in Public Health at the University of Valencia (1992). I am specialised in Preventive Medicine and Public Health at the University Dr. Peset Hospital (Valencia, 1994). I have managed the unit of Clinical and Epidemiological Research as an epidemiologist from 1994-2006 at this hospital, which has become a Foundation (presently undergoing changes). Furthermore, Dr. Morales is a member of the Royal Academy of Medicine (Valencia), a referee for various journals, and she collaborates with the Spanish Ministry of Health. María Morales has written widely on numerous aspects of preventive medicine and public health in several International Journals according to the Medical Science Citation Index. In the last 5 years, she has worked on European projects, Bio-med, rare cancers led by Prof. Olsen and Elsbeth Lynge (both from Denmark), she has collaborated with the Thames Cancer Research (T.C.R.) on several occasions, and she presently collaborates with the Danish National Cohort (D.N.C. Aarhus University, Denmark), and also in coordination with Valencia on the ISAAC I, II and III projects on Asthma, Atopic Dermatitis in Children with the New Zealand University. She has been involved in 311 published articles, a similar number of communications and has led some 30 doctorate theses. She has undertaken an environmental project on Water, Residues and Atmospheric Quality. Presently, she is working on several Perinatology projects within the D.N.C., and the T.C.R.Read More

General Manager & Treasurer eclecTechs™, LLC 22 Cherry Street Westfield, MA 01060 info@eclecTechs.com www.eclecTechs.com Barbara has been the General Manager at eclecTechs since 1998. eclecTechs offers many Internet services, including Web Design, Programming, Networking and Consulting. eclecTechs also offers DSL and web hosting at reasonable rates. Barbara received a degree in Accounting from The University of Massachusetts in 1989.Read More

Director of Prenatal Diagnosis and Fetal Therapy Unit Assistant Professor of Obstetrics and Gynecology Department of Gynecological Science and Human Reproduction, Section of Maternal and Fetal Medicine University of Padua School of Medicine via Giustiniani N 3, Padua, 35128, Italy Phone: +39-339-8146745 Fax: +39-049-8211842 email: ecosmi@hotmail.com Erich Cosmi was born in Rome, Italy on December 1st, 1973. He entered the school of Medicine and Surgery at the University of Rome “La Sapienza”, Rome, Italy in the 1993-1994 academic year, and was graduated on July 13th, 1999 summa with Laude, discussing his scientific work entitled: new therapeutical prevention of NRDS by in-utero surfactant administration. During his scholarship, Erich Cosmi was invited for three consecutive periods (1994-1996-1998), each period lasting three months, at the Yale University School of Medicine, Connecticut, USA, where he worked with Dr. Gabor Huszar in the Physiology Sperm laboratory and entered in a Research program concerning Reproductive Medicine. During his scholarship in Italy he attended as a student in the following Departments: Department of Anatomy: 1994-1995 Department of Pediatric Surgery: 1996-1997 Department of Anesthesiology: 1997-1998 Department of Obstetrics and Gynecology: 1998-1999 After his graduation in Medicine he attended the rotation as a Medical Doctor for 6 months in Internal Medicine, General Surgery, Pediatric and Ob/Gyn, Emergency and intensive Care Unit Departments. In the academic year of 1999-2000 he entered the residency school in Ob/Gyn at the University of Rome “Tor Vergata”, Rome, Italy. In April 2001 he was appointed Assistant Professor in the Department of Obstetrics and Gynecology at the Virginia University (USA) School of Medicine for 3 years, were he was involved in many research projects in maternal-fetal medicine. From 2001 to 2004 was appointed Assistant Professor of Obstetrics and Gynecology and Associate Chief of MFM at the University of Sassari School of Medicine (Italy). He is assistant researcher at the Yale University School of medicine, Connecticut, USA. He is supervisor for Fetal Anemia at the University of Rome La Sapienza, Rome, Italy. From September 1st 2001 he was appointed as Assistant Professor of Obstetrics and Gynecology in University of Sassari School of Medicine, Italy. Till November 2001 he was involved with the residency program development in Obstetrics and Gynecology at the University of Sassari School of Medicine. From November 1st 2004 he was appointed Assistant Professor of Obstetrics and Gynecology in University of Padua School of Medicine. Erich Cosmi is author of 220 publications, with Impact Factor of 135, Citation Index of 324 and H- index of 10. From 2005 is Visiting Professor at the III University of Athens, Greece. From 13/09/05 is Tresourer and Counselor of the Italian Society of Maternal Fetal Medicine. International Member of the International Society of Ultrasound in Obstetrics and Gynecology from 2000; Member of The American Institute of Ultrasound in Medicine from 2005. Honorary Member of The Academy of Medicine of Serbia Montenegro. Expert Referee for ECM in Medicine appointed from 2005 by the Ministry of Health. From 2007 he is listed in the following encyclopedias: Who is Who in the World, Who is Who in Science and Engineering, Who is Who in America. From 2007 he is Director of the prenatal diagnosis and fetal therapy Unit in the Department of Obstetrics and Gynecology at Padua University.Read More

FAX: 91-0172-744401,745078 E-mail: medinst@pgi.chd.nic.in Website. http.//pgimer.nic.in (Off.) .745062 Phone: PBX .747585 Ext.5555 Resi. : 746868/746688 POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH -160 012 (India) Prof. S.K. Sharma M.S., M.Ch. (Urology), F.A.M.S. Director Dated: 27.11.02 Sub.: Worldwide proficiency of health services in collaboration with United Nations Association of USA (UNA-USA) and WomensHealthSection.Com, and all countries willing to participate in the project. ******* Dear Dr. Luthra, Kindly refer to your communication dated 21st August, 2002 which reached me through Dr. (Mrs.) S. Kataria, Ex-Director General Health Services, UT, Chandigarh with respect to the above mentioned subject. I remember Dr. Kataria having discussed this issue with me last year also but somehow I was not able to write to you. I appreciate WomensHealthSection.com and United Nations Association of USA for their efforts in helping countries and institutions to build a teaching curriculum. We would be very much interested to be a part of this programme and I would wish that sometime when you are in Chandigarh, we could talk over this project along with the Head, Departments of Obstetrics & Gynaecology and Psychiatry, PGI. It was pleasure to know that you are ex-postgraduate student of this Institute and it would be our pleasure to associate with you for the betterment of any teaching programme for the Institute. With regards, Yours sincerely, (S.K. Sharma) Dr. Rita Luthra, MD Director, Women’s Health & Education Center, 300 Stafford Street, Suite 265, SPRINGFIELD, MA 01104, USA.Read More